Autologous Fixed Tumor Vaccine: A Formulation with Cytokine‐microparticles for Protective Immunity against Recurrence of Human Hepatocellular Carcinoma
| Autor: | Liang Lj, Lan Huang, Jiefu Huang, Kam W. Leong, Saeri Totsuka, Bao Gang Peng, Ming Kuang, Ming-De Lu, Qiang He, Tadao Ohno, Shu Qin Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Interleukin 2
Male Cancer Research Carcinoma Hepatocellular Time Factors Hepatocellular carcinoma medicine.medical_treatment Cancer Vaccines Mice Recurrence Cell Line Tumor medicine Carcinoma Animals Humans Adverse effect Clinical Trials as Topic Dose-Response Relationship Drug business.industry Liver Neoplasms Immunotherapy medicine.disease Tumor vaccine Clinical trial Mice Inbred C57BL Granulocyte macrophage colony-stimulating factor Cytokine Oncology Immunology Cancer research Cytokines Female business Adjuvant Rapid Communication Neoplasm Transplantation medicine.drug |
| Zdroj: | Japanese Journal of Cancer Research : Gann |
| ISSN: | 1876-4673 0910-5050 |
| Popis: | We developed a tumor vaccine consisting of fixed hepatocellular carcinoma (HCC) cells/tissue fragments, biodegradable microparticles encapsulating granulocyte-macrophage-colony stimulating factor and interleukin-2, and an adjuvant. The vaccine protected 33% of syngeneic mice from HCC cell challenge. The vaccine containing human autologous HCC fragments showed essentially no adverse effect in a phase I/IIa clinical trial and 8/12 patients developed a delayed-type hypersensitivity (DTH) response against the fragments. Although 2 of 4 DTH-response-negative patients had recurrence after curative resection, the DTH-response-positive patients had no recurrence. The time before the first recurrence in the vaccinated patients was significantly longer than that in 24 historical control patients operated in the same department (P < 0.05). This formulation is a promising candidate to prevent recurrence of human HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text